DPP4 and diabetes mellitus: DPP4 inhibitors like APL and PVI are potential antidiabetic peptides for lowering glycemic indices, lowering the amount of glucagon, and maintaining insulin levels in type 2 diabetes mellitus [90], and their activities are indirectly facilitated by the continuous presence of GLP-1 incretin [91].